Ligand Pharmaceuticals
Prix: 255.54Entreprise et modèle économique
Ligand Pharmaceuticals is a biotechnology company focused on developing and commercializing technologies that enhance drug discovery and development. Its core products include a range of proprietary technologies and partnered programs that facilitate the creation of therapeutics across various disease areas. Major business segments include royalty revenue from partnered products and licensing agreements. The primary revenue sources stem from collaborations with pharmaceutical companies and royalties from sales of drugs utilizing Ligand's technologies.
Profil d’investissement
The investment profile of Ligand Pharmaceuticals is more aligned with value investors, given its current market position and revenue trends. The stock may appeal to those seeking potential long-term appreciation, although recent performance indicates challenges. Investors should consider the company's volatility and risk factors when evaluating their investment horizon.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 7.84 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -13.3% ↓
- Surprise BPA
- -11.4% moins bon que prévu
- Volatilité 20 j
- 1.8% stable
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-05-24 02:44 | Vendre | Conserver | Weak fundamentals and high risk limit upside potential. |
| 2026-05-16 02:46 | Conserver | Vendre | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 15:20 | — | Conserver | Weak fundamentals and negative momentum raise concerns. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-04-30 10:09 | H.C. Wainwright | Objectif relevé | 243 → 289 | 224.86 |
| 2026-04-28 11:36 | RBC Capital | Objectif relevé | 235 → 252 | 241.79 |
| 2026-04-27 18:05 | Stifel Nicolaus | Objectif relevé | 230 → 255 | 241.79 |
Rien pour le moment